Evidence map›Paper›PMID 29071398›Full record

ArticleDer Urologe. Ausg. A2018

[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data].

J E Gschwend, P Albers, M Bögemann, P Goebell, A Heidenreich, J Klier, F König, S Machtens, K Pantel, C Thomas

Abstract read
PubMed Publisher
In one paragraph

Article in Der Urologe. Ausg. A, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

J E GschwendKlinik und Poliklinik für Urologie, Universitätsklinikum rechts der Isar der Technischen Universität München, Ismaninger Straße 22, 81675, München, Deutschland. juergen.gschwend@tum.de.
P AlbersUrologische Klinik und Poliklinik, Universität Düsseldorf, Düsseldorf, Deutschland.
M BögemannKlinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Münster, Deutschland.
P GoebellUrologische Klinik, Universitätsklinikum Erlangen, Erlangen, Deutschland.
A HeidenreichKlinik und Poliklinik für Urologie, Universitätsklinik Köln, Köln, Deutschland.
J KlierUrologie Bayenthal, Gemeinschaftspraxis Köln, Köln, Deutschland.
F KönigATURO, Praxis für Urologie, Berlin, Deutschland.
S MachtensKlinik für Urologie und Kinderurologie, Marien-Krankenhaus gGmbH Bergisch Gladbach, Bergisch Gladbach, Deutschland.
K PantelInstitut für Tumorbiologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
C ThomasUrologische Klinik und Poliklinik, Universitätsmedizin Mainz, Johannes Gutenberg-Universität Mainz, Mainz, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAt the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented.

objectivesThe focus is on the clinical impact of these data. MATERIALS AND

methodsA group of German experts in the field of urogenital-oncologic expertise discussed the clinical impact with respect to the current data.

resultsThe study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients with mCRPC.

conclusionsCabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20 mg/m

Indexed as

DocetaxelHumansMaleNeoplasms, Second PrimaryProstatic Neoplasms, Castration-ResistantTaxoidscabazitaxelDocetaxelTaxoidsCabazitaxelDocetaxelPatient selectionProstate cancer, metastatic castration-resistantTherapy, endocrine

Identifiers

PMID29071398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.